



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Xtandi

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification ¹ issued on	Commission Decision Issued ² / amended on	Product Information affected ³	Summary
II/0068/G	This was an application for a group of variations. Grouped application comprising two type II variations as follows: C.I.4 - Update of sections 4.2, 4.4 and 4.8 in order to add a new warning on Dysphagia and to add	16/01/2025		SmPC and PL	SmPC new text 4.2 Posology and method of administration Swallowing difficulties/history of dysphagia population Enzalutamide is also available as tablets (40 mg and 80 mg) for patients who have difficulties swallowing large capsules or for patients with a history of dysphagia.

¹ Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

² A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

³ SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).



	dysphagia to the list of adverse drug reactions (ADRs) with frequency Not known based on the cumulative review of the MAH safety database and literature search. C.I.4 – Update of section 4.8 of the SmPC in order to add decreased appetite to the list of adverse drug reactions (ADRs) with frequency Not known based on the cumulative review of the MAH safety database and literature search. The Package Leaflet is updated accordingly. Changes are also made to the PI and PL to bring them in line with the current QRD template version 10.4. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data				4.4 Special warnings and precautions for use Dysphagia related to product formulation There have been reports of patients experiencing difficulty swallowing Xtandi, including reports of choking. The swallowing difficulties and choking events were mostly reported with the capsule formulation, which could be related to a larger product size. Patients should be advised to swallow the capsules whole with a sufficient amount of water. In patients who have difficulties swallowing large capsules or patients with a history of dysphagia, it is recommended to use enzalutamide tablet formulations instead. 4.8 Undesirable effects Table 1: Adverse reactions identified in controlled clinical trials and post-marketing Metabolism and nutrition disorders Not known*: decreased appetite Gastrointestinal disorders Not known*: dysphagia, For more information, please refer to the updated Summary of Product Characteristics.
IA/0067/G	This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites	27/06/2024	n/a		

	(excluding manufacturer for batch release) A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)				
PSUSA/10095 /202308	Periodic Safety Update EU Single assessment - enzalutamide	25/04/2024	20/06/2024	SmPC and PL	Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10095/202308.
IAIN/0066	A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release	06/06/2024		SmPC, Annex II and PL	
II/0063	Extension of indication for Xtandi to include treatment as monotherapy or in combination with androgen deprivation therapy of adult men with high risk biochemical recurrent (BCR) non-metastatic hormone sensitive prostate cancer (nmHSPC) who are unsuitable for salvage radiotherapy, based on final results from study MDV3100-13 (EMBARK); this is a phase 3, randomized, efficacy and safety study of enzalutamide plus leuprolide, enzalutamide monotherapy, and placebo plus leuprolide in men with high-risk nonmetastatic prostate cancer progressing after definitive therapy. As a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. The RMP version 18 is approved. In addition, the MAH took the opportunity to introduce minor changes to the PI and to update the list of local representatives in the Package	21/03/2024	19/04/2024	SmPC and PL	Please refer to Scientific Discussion Xtandi-H-C-002639 -II-0063

	Leaflet. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one				
IA/0064/G	This was an application for a group of variations. B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS	20/10/2023	n/a		
IA/0062	B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the originally approved batch size	01/06/2022	n/a		
IB/0061	B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)	24/05/2022	06/03/2023	SmPC	
IAIN/0060	C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	04/05/2022	06/03/2023	SmPC	
IA/0059/G	This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or	28/03/2022	n/a		

	intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient				
II/0058	Update of section 4.5 in order to add information regarding drug-drug interaction based on final results from study 9785-CL-0018 - A Phase 1 Open-label Study to Evaluate the Effect of Multiple Doses of Enzalutamide on the Pharmacokinetics of Substrates of P-glycoprotein (Digoxin) and Breast Cancer Resistant Protein (Rosuvastatin) in Male Subjects with Prostate Cancer. Additionally, the MAH has taken the opportunity to make an update to the information about the	17/03/2022	06/03/2023	SmPC and PL	Results from study 9785-CL-0018 showed a mild inhibitory effect of enzalutamide, at steady state, on P-gp in patients with prostate cancer that received a single oral dose of the probe P-gp substrate digoxin before and concomitantly with enzalutamide. Medicinal products with a narrow therapeutic range that are substrates for P gp (e.g. colchicine, dabigatran etexilate, digoxin) should be used with caution when administered concomitantly with Xtandi and may require dose adjustment to maintain optimal plasma concentrations. The same study 9785-CL-0018 showed that

	excipients in Section 4.4 of the SmPC, to introduce editorial changes in the SmPC and in the Package Leaflet, and to update the list of local representatives in the Package Leaflet. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data				at steady state, enzalutamide did not cause a clinically meaningful change in exposure to the probe breast cancer resistance protein (BCRP) substrate rosuvastatin in patients with prostate cancer that received a single oral dose of rosuvastatin before and concomitantly with enzalutamide. No dose adjustment is necessary when a BCRP substrate is co administered with Xtandi. For more information, please refer to the Summary of Product Characteristics.
II/0057	Update of sections 4.8, 5.1 and 5.2 of the SmPC in order to reflect the updated safety and efficacy data from the final analysis of the 9785-CCL-0335 (ARCHES) study, a phase 3 randomized, double-blind, placebo-controlled study that evaluated the safety and efficacy of enzalutamide plus androgen deprivation therapy (ADT) vs. placebo plus ADT in men with mHSPC; the Package Leaflet is updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data	10/03/2022	06/03/2023	SmPC and PL	Updated safety and efficacy data from the final analysis of the 9785-CCL-0335 (ARCHES) were submitted. At the pre specified final analysis for overall survival, conducted when 356 deaths were observed, a statistically significant 34% reduction in the risk of death was demonstrated in the group randomised to receive enzalutamide compared with the group randomised to receive placebo. For more information, please refer to the Summary of Product Characteristics.
IA/0056	B.III.1.b.2 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - New certificate for a starting material/reagent/intermediate/or excipient from a new or an already approved manufacturer	05/08/2021	n/a		
PSUSA/10095	Periodic Safety Update EU Single assessment -	22/04/2021	17/06/2021	SmPC	Refer to Scientific conclusions and grounds recommending

/202008	enzalutamide				the variation to terms of the Marketing Authorisation(s)' for PSUSA/10095/202008.
II/0047/G	This was an application for a group of variations. C.1.6: Extension of Indication to include the treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) for Xtandi in combination with androgen deprivation therapy based on the data of study 9785-CL-0335 (ARCHES). As a consequence, sections 4.1, 4.2, 5.1, and 6.6 of the SmPC are updated. Furthermore the MAH took the opportunity to make corrections to section 4.7. The Package Leaflet is updated in accordance. The RMP version 13.0 is approved. C.1.4: Update of section 5.1 of the SmPC based the 5-year Overall Survival (OS) results obtained from the PREVAIL study (MDV310003), a phase 3 study of enzalutamide in chemotherapy naïve patients with metastatic prostate cancer that progressed on ADT. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data	25/03/2021	30/04/2021	SmPC and PL	Please refer to Scientific Discussion Xtandi-H-C-002639 -II-0047/G
IB/0055/G	This was an application for a group of variations. B.I.a.1.f - Change in the manufacturer of AS or of a	17/03/2021	n/a		

	starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation				
II/0050	Update of section 4.4 of the SmPC in order to add a warning on severe cutaneous adverse reactions based on a safety review; the Package Leaflet is updated accordingly C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data	04/03/2021	30/04/2021	SmPC and PL	Severe cutaneous adverse reactions (SCARs) have been reported with enzalutamide. At the time of prescription patients should be advised of the signs and symptoms and monitored closely for skin reactions.
IB/0054	B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation	01/02/2021	n/a		
II/0049	Update of sections 4.4, 4.7, 4.8, 5.1, 5.2 and 5.3 of the SmPC in order to update efficacy and safety information and include a warning on the risk of second primary malignancies based on final results from study MDV3100-14 (PROSPER) listed as a PAES in the Annex II; this is a phase 3, randomized, double-blind, placebo-controlled, efficacy and safety study of enzalutamide in patients with nonmetastatic castration-resistant prostate cancer; the Package Leaflet and Annex II are updated accordingly. The RMP version 15.0 is approved. In addition, the MAH	28/01/2021	30/04/2021	SmPC, Annex II, Labelling and PL	At the final analysis for overall survival in Study MDV3100-14 (PROSPER), conducted when 466 deaths were observed, a statistically significant improvement in overall survival (OS) was demonstrated in patients randomised to receive enzalutamide compared with patients randomised to receive placebo with a 26.6% reduction in risk of death [hazard ratio (HR) = 0.734, (95% CI: 0.608; 0.885), p = 0.0011]. The median OS was 67.0 months (95% CI: 64.0, NR) in the enzalutamide group and 56.3 months (95% CI: 54.4, 63.0) in the placebo group. The median follow-up time was 48.6 and 47.2 months for the enzalutamide and

	took the opportunity to update the list of local representatives in the Package Leaflet, make few editorial updates and bring the PI in line with the latest QRD template version 10.1. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data				placebo groups, respectively. Thirty-three percent of enzalutamide-treated and 65% of placebo-treated patients received at least one subsequent antineoplastic therapy that may prolong overall survival. Cases of second primary malignancies have been reported in patients treated with enzalutamide in clinical studies. In phase 3 clinical studies, the most frequently reported events in enzalutamide treated patients, and greater than placebo, were bladder cancer (0.3%), adenocarcinoma of the colon (0.2%), transitional cell carcinoma (0.2%) and bladder transitional cell carcinoma (0.1%). Patients should be advised to promptly seek the attention of their physician if they notice signs of gastrointestinal bleeding, macroscopic haematuria, or other symptoms such as dysuria or urinary urgency develop during treatment with enzalutamide.
IAIN/0052/G	This was an application for a group of variations. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer	09/11/2020	n/a		

	B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer A.7 - Administrative change - Deletion of manufacturing sites				
IB/0051/G	This was an application for a group of variations. B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch-release, batch control, primary and secondary packaging, for non-sterile medicinal products B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the originally approved batch size B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure	29/10/2020	n/a		
IB/0048	C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation	14/02/2020	04/02/2021	Annex II	
IA/0046	A.7 - Administrative change - Deletion of manufacturing sites	04/03/2019	n/a		

IB/0044	B.II.f.1.z - Stability of FP - Change in the shelf-life or storage conditions of the finished product - Other variation	15/01/2019	n/a		
IB/0045	B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate	09/01/2019	n/a		
II/0039/G	This was an application for a group of variations. Extension of Indication to include adult men with high-risk non-metastatic castration-resistant prostate cancer (CRPC) The Package Leaflet is updated in accordance. Update of SmPC to amend the warning on possible association with seizure, to amend the effects on driving or operating machines, to amend the identified adverse reactions and to amend the 'Race' subsection regarding pharmacokinetic properties based on the results from the completed studies PROSPER (Phase 3 Randomized Controlled Study) and Asian PREVAIL (Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study) and the updated integrated clinical safety database. The Package Leaflet is updated in accordance. In addition, the Product Information was updated according to the latest QRD template.	20/09/2018	23/10/2018	SmPC, Annex II, Labelling and PL	Please refer to the scientific discussion Xtandi EMEA/H/C/002639/II/0039G.

	C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one				
IB/0043/G	This was an application for a group of variations. B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter) B.I.b.2.c - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure for a reagent, which does not have a significant effect on the overall quality of the AS B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.c.2.z - Change in the specification parameters	01/10/2018	n/a		

	and/or limits of the immediate packaging of the AS - Other variation B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place				
IB/0042/G	This was an application for a group of variations. B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size	08/08/2018	n/a		
IB/0041	B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation	19/04/2018	n/a		
IB/0040	B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data	18/04/2018	n/a		
PSUSA/10095 /201708	Periodic Safety Update EU Single assessment - enzalutamide	08/03/2018	n/a		PRAC Recommendation - maintenance

R/0037	Renewal of the marketing authorisation.	14/12/2017	08/02/2018	SmPC, Labelling and PL	Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Xtandi in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity.
X/0029	Annex I_2.(c) Change or addition of a new strength/potency Annex I_2.(d) Change or addition of a new pharmaceutical form	20/07/2017	21/09/2017	SmPC, Labelling and PL	
II/0035	Update of sections 4.4 and 4.8 of the SmPC to reflect the final results of the post authorisation safety study (PASS) CL-9785-0403 which evaluated the risk of seizure among subjects with mCRPC treated with enzalutamide who were at potential increased risk of seizure (UPWARD) and was listed as a category 3 in the RMP. The RMP version 11.0 has also been submitted. In addition, the Marketing authorisation holder (MAH) took the opportunity to make a correction in section 5.1 of the SmPC. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data	09/06/2017	21/09/2017	SmPC	Section 4.8 of the SmPC reflects that 8 of 366 (2.2%) patients treated with enzalutamide in study 9785-CL-0403 experienced a seizure. The duration of treatment was 9.3 months. Section 4.4 warns and advises prescribing physicians, that in case of seizures the decision for treatment continuation should be taken on a case by case basis. The updated RMP version 11.0 is accepted.
II/0034	Update of section 5.1 of the SmPC in order to reflect relevant information for physicians namely on the observed differences in treatment effect based on prior chemotherapy treatment history. In addition, the MAH took this opportunity to reflect	18/05/2017	21/09/2017	SmPC	Section 5.1 of the SmPC reflects comprehensive data on observed differences in treatment effect based on prior chemotherapy treatment history. Results of the PREVAIL and TERRAIN trials in prior chemo-naïve patients and results of study 9785-CL-0410 in patients previously

	the ATC code for enzalutamide. The RMP version 11.0 has also been submitted. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data				treated with at least 24 weeks of abiraterone (plus prednisone) are included in the SmPC. The updated RMP version 11.00 is accepted.
II/0036	Update of sections 4.6 and 5.3 of the SmPC to reflect the final results of study AE-7592-G, "Transfer of Radioactivity into Fetuses and Breast Milk in Rats after a Single Oral Administration of [¹⁴C] MDV3100- ISN: 9785-ME-0046". The Package Leaflet is updated accordingly. The RMP version 11.0 has also been submitted. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data	09/03/2017	21/09/2017	SmPC and PL	Results of a non-clinical study in pregnant rats have shown that enzalutamide and/or its metabolites are transferred to fetuses. Therefore enzalutamide may cause harm to the unborn child or potential loss of pregnancy if taken by women who are pregnant. This study also showed that enzalutamide and/or its metabolites are secreted in rat milk. It is not known if enzalutamide is present in human milk but its use has always been contraindicated in women who are or may become pregnant.
PSUSA/10095 /201608	Periodic Safety Update EU Single assessment - enzalutamide	09/03/2017	n/a		PRAC Recommendation - maintenance
IB/0032	C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	16/08/2016	n/a		
IB/0030/G	This was an application for a group of variations. B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other	07/07/2016	n/a		

	variation				
IAIN/0031	B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site	09/06/2016	n/a		
II/0028/G	This was an application for a group of variations. Update of sections 4.8 and 5.1 of the SmPC based on the results of study 9785-CL-0222 (TERRAIN); an active-controlled study, which evaluated the safety and efficacy of enzalutamide vs bicalutamide in men with metastatic CRPC. The Package Leaflet has been updated accordingly. Further, the MAH provides supportive data from study MDV3100-09 (STRIVE), a second phase 2 study of enzalutamide vs bicalutamide. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority	01/04/2016	12/12/2016	SmPC and PL	The TERRAIN study enrolled 375 chemo- and antiandrogen-therapy naïve patients who were randomized to receive either enzalutamide at a dose of 160 mg once daily (N = 184) or bicalutamide at a dose of 50 mg once daily (N = 191). Median PFS was 15.7 months for patients on enzalutamide versus 5.8 months for patients on bicalutamide [HR = 0.44 (95% CI: 0.34, 0.57), p < 0.0001]. Progression-free survival was defined as objective evidence of radiographic disease progression by independent central review, skeletal related events, initiation of new antineoplastic therapy or death by any cause, whichever occurred first. Consistent PFS benefit was observed across all pre-specified patient subgroups. Safety data presented are within the known safety profile of enzalutamide.
PSUSA/10095 /201508	Periodic Safety Update EU Single assessment - enzalutamide	17/03/2016	n/a		PRAC Recommendation - maintenance
II/0026	C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated	17/12/2015	12/12/2016	Annex II	

	by new additional data to be submitted by the MAH where significant assessment is required				
PSUSA/10095/201502	Periodic Safety Update EU Single assessment - enzalutamide	24/09/2015	27/11/2015	SmPC and PL	Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10095/201502.
IB/0025	B.I.a.z - Change in manufacture of the AS - Other variation	12/10/2015	n/a		
II/0020/G	This was an application for a group of variations. Update of section 4.5 of the SmPC in order to update information on drug-drug interactions after analysis of studies 9785-CL-0405 and 9785-CL-0406. The Package Leaflet is updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data	17/09/2015	27/11/2015	SmPC and PL	Following oral administration of the moderate CYP2C8 and strong CYP3A4 inducer rifampin (600 mg once daily) to healthy male subjects, the AUC of enzalutamide plus the active metabolite decreased by 37% while Cmax remained unchanged. No dose adjustment is necessary when Xtandi is co-administered with inducers of CYP2C8 or CYP3A4. Enzalutamide (160 mg once daily) did not cause a clinically relevant change in the AUC or Cmax of caffeine (CYP1A2 substrate) or pioglitazone (CYP2C8 substrate). The AUC of pioglitazone increased by 20% while Cmax decreased by 18%. The AUC and Cmax of caffeine decreased by 11% and 4%, respectively. No dose adjustment is indicated when a CYP1A2 or CYP2C8 substrate is co-administered with Xtandi.
IB/0023	C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	25/08/2015	n/a		
IA/0024/G	This was an application for a group of variations. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS	23/07/2015	n/a		

	B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size				
IA/0022/G	This was an application for a group of variations. B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size B.I.a.3.b - Change in batch size (including batch size ranges) of AS or intermediate - Downscaling down to 10-fold	26/06/2015	n/a		
IB/0019/G	This was an application for a group of variations. B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold	24/06/2015	n/a		

	increase compared to the originally approved batch size B.I.a.4.b - Change to in-process tests or limits applied during the manufacture of the AS - Addition of a new in-process test and limits B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation				
II/0015	Update of sections 4.2, 4.4 and 5.2 of the SmPC in order to update the safety and pharmacokinetic information in hepatic impairment after finalisation of the study 9785-CL-0404. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data	21/05/2015	22/06/2015	SmPC	No dose adjustment is necessary for patients with mild, moderate, or severe hepatic impairment (Child-Pugh Class A, B, or C, respectively). An increased drug half-life has however been observed in patients with severe hepatic impairment.
PSUSA/10095/201408	Periodic Safety Update EU Single assessment - enzalutamide	26/03/2015	27/05/2015		Please refer to Xtandi-EMA/H/C/PSUSA/10095/201408 EPAR: Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation.
II/0018	Update of section 5.1 of the SmPC in order to update the Pharmacodynamic properties information regarding Overall Survival (OS) after analysis of data from the PREVAIL (MDV3100-03) study satisfying part of the Obligation to conduct post-authorisation measures as reported in the annex II. The annex II is updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance	23/04/2015	22/06/2015	SmPC and Annex II	At the pre-specified interim analysis for overall survival when 540 deaths were observed, treatment with enzalutamide demonstrated a statistically significant improvement in overall survival compared to treatment with placebo with a 29.4% reduction in risk of death [HR=0.706, (95% CI: 0.596; 0.837), p < 0.0001]. An updated survival analysis was conducted when 784 deaths were observed. Results from this analysis were consistent with those from the interim analysis (Table 2, Figure 1). At the updated analysis 52% of enzalutamide-treated and

	data				81% of placebo-treated patients had received subsequent therapies for metastatic CRPC that may prolong overall survival.
II/0016	Update of sections 4.4 and 4.8 of the SmPC in order to add a warning and update the safety information on posterior reversible encephalopathy syndrome (PRES) following analysis of post-marketing case reports. The Package Leaflet is updated accordingly. In addition, the Marketing authorisation holder (MAH) took the opportunity to correct typographical and formatting errors in the SmPC. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data	26/03/2015	27/05/2015	SmPC and PL	There have been rare reports of posterior reversible encephalopathy syndrome (PRES) in patients receiving Xtandi. PRES is a rare, reversible, neurological disorder which can present with rapidly evolving symptoms including seizure, headache, confusion, blindness, and other visual and neurological disturbances, with or without associated hypertension. A diagnosis of PRES requires confirmation by brain imaging, preferably magnetic resonance imaging (MRI). Discontinuation of Xtandi in patients who develop PRES is recommended.
IB/0017	B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data	03/02/2015	n/a		
IB/0014	To introduce the changes requested by PRAC and CHMP in September 2014, to add the signals of QT interval prolongation due to long term use for medicinal products for androgen deprivation therapy. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	16/01/2015	27/05/2015	SmPC and PL	
IB/0012/G	This was an application for a group of variations.	09/12/2014	27/05/2015	SmPC	

	B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data) B.II.f.1.z - Stability of FP - Change in the shelf-life or storage conditions of the finished product - Other variation				
II/0008	Extension of indication for the treatment of adult men with metastatic castration-resistant prostate cancer who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated. As a consequence, section 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC and the package leaflet have been updated accordingly. Annex II has also been updated to include an obligation to conduct a post-authorisation measure. The MAH also propose to update the contact details of local representatives in the package leaflet. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one	23/10/2014	28/11/2014	SmPC, Annex II and PL	Please refer to Scientific Discussion Xtandi-H-2639-II-08 AR.
IB/0011	B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation	25/09/2014	n/a		
II/0007/G	This was an application for a group of variations. Update of sections 4.4 and 4.5 of the SmPC further to the results of a study investigating the interaction	25/09/2014	28/11/2014	SmPC	In a clinical study in patients with metastatic CRPC, Xtandi (160 mg once daily) had no clinically relevant effect on the pharmacokinetics of intravenously administered docetaxel (75 mg/m2 by infusion every 3 weeks). The AUC of

	with docetaxel. Section 4.5 of the SmPC is also updated further to results of a study of enzymes induced by Xtandi. Section 5.2 is updated further to the results of a study investigating the transport of the metabolite M2 by BCRP, of a study to assess protein binding displacement between Xtandi and other medicinal products, of two studies investigating the in vitro metabolism of ¹⁴C-M2, and of a pharmacokinetic study in Japanese patients. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data				docetaxel decreased by 12% [geometric mean ratio (GMR) =0.882 (90% CI: 0.767, 1.02)] while C_{max} decreased by 4% [GMR = 0.963 (90% CI: 0.834, 1.11)]. Co-administration of enzalutamide has no clinically relevant effect on the pharmacokinetics of intravenous docetaxel; however, an increase in the occurrence of docetaxel-induced neutropenia cannot be excluded. Enzymes that may be induced by enzalutamide include CYP2B6 but not CYP1A2 and patients taking medicinal products that are substrates of CYP2B6 should be evaluated for possible loss of pharmacological effects (or increase in effects in cases where active metabolites are formed) during the first month of enzalutamide treatment, and dose adjustment should be considered as appropriate. Enzalutamide is 97% to 98% bound to plasma proteins, primarily albumin. The active metabolite is 95% bound to plasma proteins. There was no protein binding displacement between enzalutamide and other highly bound drugs (warfarin, ibuprofen and salicylic acid) in vitro. Enzalutamide is extensively metabolized. There are two major metabolites in human plasma: N desmethyl enzalutamide (active) and a carboxylic acid derivative (inactive). In vitro, N-desmethyl enzalutamide is metabolized to the carboxylic acid metabolite by carboxylesterase 1, which also plays a minor role in the metabolism of enzalutamide to the carboxylic acid metabolite. N desmethyl enzalutamide was not metabolized by CYPs in vitro. In vitro data indicate that N-desmethyl enzalutamide is not a substrate for P-gp or BCRP. Based on pharmacokinetic data from a study in Japanese patients with prostate cancer, there were no clinically
--	--	--	--	--	--

					relevant differences in exposure between Japanese and Caucasians. There are insufficient data to evaluate potential differences in the pharmacokinetics of enzalutamide in other races.
II/0006/G	This was an application for a group of variations. Update of section 5.3 of the Summary of Product Characteristics further to the results of embryo-foetal development studies in mice and rabbits and repeat dose toxicity studies in dogs. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data	25/09/2014	28/11/2014	SmPC	Enzalutamide treatment of pregnant mice resulted in an increased incidence of embryo-fetal deaths and external and skeletal changes. Consistent with the pharmacological activity of enzalutamide, atrophy, aspermia/hypospermia and hypertrophy/hyperplasia in the reproductive system were noted in dogs (39 weeks). In studies in mice (4 weeks) and dogs (39 weeks), changes in the reproductive organs associated with enzalutamide were decreases in organ weight with atrophy of the prostate and epididymis. Leydig cell hypertrophy and/or hyperplasia were observed in mice (4 weeks) and (dogs 39 weeks).
IB/0010	To update section 4.8 with undesirable effects with unknown frequency in the section on musculoskeletal and connective tissue disorders of the SmPC and package leaflet following a recommendation by PRAC. In addition the presentation of the side effects in this section have been updated to the latest QRD template. Furthermore minor corrections to the FR annexes were implemented to bring it in line with the EN annexes. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	17/09/2014	28/11/2014	SmPC and PL	

PSUV/0009	Periodic Safety Update	10/07/2014	n/a		PRAC Recommendation - maintenance
IAIN/0005	C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location	10/03/2014	n/a		
IA/0004/G	This was an application for a group of variations. B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS	18/12/2013	n/a		
IA/0003/G	This was an application for a group of variations. B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished	16/12/2013	n/a		

	product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure				
IAIN/0002/G	This was an application for a group of variations. C.I.9.a - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the QPPV and/or QPPV contact details and/or back-up procedure C.I.9.c - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the PhV system	20/09/2013	n/a		
IAIN/0001	C.I.9.i - Changes to an existing pharmacovigilance system as described in the DDPS - Change(s) to a DDPS following the assessment of the same DDPS in relation to another medicinal product of the same MAH	06/08/2013	n/a		